THREE-DIMENSIONAL ULTRASONOGRAPHIC ASSESSMENT OF ABNORMAL UTERINE BLEEDING IN INTRAUTERINE CONTRACEPTIVE DEVICE USERS

Thesis Submitted in the fulfillment of Master degree in Obstetrics & Gynecology

By
Rehab Lofty Mohammed
M.B, B.CH.
Cairo University

Supervised by

Dr. Ayman Abdel-Haleem Marzouk

Professor of Obstetrics & Gynecology Faculty of Medicine-Cairo University

Dr. Mostafa Mohammed Abdel-Bar

Assistant Professor of Obstetrics & Gynecology Faculty of Medicine-Cairo University

Faculty of Medicine Cairo University 2009

بسم الله الرحمن الرحيم

" قالوا سبحانك لاعلم لنا إلا ما علمتنا إنك أنت العليم الحكيم"

صدق الله العظيم

(سورة البقرة, الآية الثانية والثلاثون)

Abstract

The first IUCD was introduced by Richter in 1909, since then many types of IUCDs were introduced. It was reported that IUCDs are used by over than 100 million women in the world. Intra uterine contraceptive device induced irregular uterine bleeding is one of the most common complications for many women using this method. Abnormal uterine bleeding due to IUCD is considered iatrogenic dysfunctional uterine bleeding. The recent use of transvaginal ultrasound is proved to provide clear images of the uterus revealing its exact size, position, myometrium and endometrium. 3D ultrasound is more accurate than 2D ultrasound for the identification and location of IUCDs. It was reported that the position of the IUCD inside the uterine cavity is related to the occurrence of abnormal uterine bleeding. The IUCD-F and IUCD-E distances were measured using 3D transvaginal ultrasound. This study revealed that there is a direct relationship between the IUCD-F and IUCD-E distances and abnormal uterine bleeding in the form of metrorrhagia, while, IUCD presence, per say, regardless its position in the uterine cavity is related to the occurane of menorrhagia

Key words:

Intra uterine contraceptive device (IUCD) and abnormal uterine bleeding

Ultrasound and bleeding

Acknowledgment

First and foremost, thanks to **ALLAH**, the most beneficent, the most merciful.

I would like to express my deepest thanks and sincere gratitude to my **Professor Dr. Ayman Abdel-Haleem Marzouk,** Professor of Obstetrics and Gynecology,

Faculty of Medicine, Cairo University, for his kind supervision, wise guidance enthusiastic encouragement, and valuable advice. I was honored and privileged to work with such a great figure in Obstetrics and Gynecology.

I am thankful and sincerely grateful to **Dr. Mostafa Mohammed Abdel-Bar,**Assistant Professor of obstetrics And Gynecology, Faculty of Medicine, Cairo
University, for his sincere supervision, honest assistance, continuous support,
and fruitful suggestions throughout the whole work, which helped to ease my
hard task of preparing this work.

I'm grateful to all my professors, assistant professors, lecturers and assistant lecturers and colleagues of the Obstetrics & Gynecology department Cairo University for their help and cooperation throughout this work

Also a lot of thanks to the staff members of the Kasr El Aini fetal medicine unit, who helped me perform the technical aspect of this work, and also for giving me the proper assistance, and opportunity to use their the facilities.

Finally, I'm grateful to the patients who cooperated with me to perform this work and for whom all our efforts are devoted.

To my parents and my sisters

Whom without their deep love, continuous care and strong support I would not be who or where I'm today.

To my fiancé

Who enlightened my way, stood by my side through all, and provided me with support, aim and direction.

Contents

I-Introduction	1
Aim of work	4
II-Intra uterine contraceptive device	
-Historical review	5
-Modern intra uterine contraceptive device	6
-Types of IUCDs.	6
Unmedicated IUCDs	6
Medicated IUCDs	7
Copper IUCDs	7
Future IUCDs	9
-Mechanism of action of IUCDs	14
-Efficacy of IUCDs	
-Timing of IUCD insertion	16
-Non contraceptive uses of IUCD	17
-Contraindications to the use of the IUCD	
Absolute contraindications	19
Relative contraindications	20
-Complications of IUCD	21
Complications of insertion	21
Expulsion	22
Perforation	23
Ectopic pregnancy	24
Actinomyces	25
Infections	25
Pregnancy with an IUCD insitu	27
Menstrual disturbances	29

III-Abnormal uterine bleeding

-Introduction.	30
-Normal menstruation.	30
-Length of normal menstruation	31
-Menstrual blood loss	31
-Duration of flow of normal menstruation	31
-Mechanism of normal menstruation	32
-Abnormal uterine bleeding	33
-Clinical types	33
Menorrhagia	
Polymenorrhoea	
Polymenorrahgia	34
Metrorrhagia	34
Menometrorrahgia	35
-Etiological classifications of dysfunctional uterine bleeding	35
Ovulatory dysfunctional uterine bleeding	35
Anovulatory dysfunctional uterine bleeding	37
-Effect of IUCD on the different aspects of endometrial haemostasis	39
IV-Three- dimensional ultrasound	
-Introduction.	42
-Physics of ultrasound.	43
-Transvaginal ultrasound.	44
-Technique of transvaginal ultrasound	44
-Three-Dimensional (3D) ultrasound.	47
-Principles of 3D ultrasound imaging.	48
-Technical aspects of 3D ultrasound	49
-3D Ultrasound offers different display options	51
2D multiplaner display of orthogonal image planes	51

Niche mode	52
3D surface-rendering mode	52
Transparency mode	52
-3D Transvaginal Ultrasound (3D-TVS)	53
-Advantages of 3D Ultrasound	54
-Factors affecting 3D image	56
-Limitations of 3D ultrasound	57
-Ultrasonographic imaging in IUCD users	59
Preinsertion Ultrasonography	59
Ultrasound imaging of Intra uterine contraceptive device	60
Ultrasound investigation of intrauterine contraceptive device	64
V-Patients and methods	
-Patients and methods	66
VI-Results	70
VII-Discussion.	105
VIII-Summary and conclusion	
-Summary	110
-Conclusion	116
XI-References	117

List of abbreviations

DUB: Dysfunctional uterine bleeding

IUCD: Intra uterine contraceptive device

IUCD-ED: Intra uterine contraceptive device-endometrium distance

IUCD-FD: Intra uterine contraceptive device-fundus distance

LNG-IUCD: Levonorgestrel intra uterine contraceptive device

LNG-IUS: *Levonorgestrel intrauterine system*

MBL: Menstrual blood loss

PID: Pelvic inflammatory disease

2D ultrasound: Two-dimensional ultrasound

3D ultrasound: Three-dimensional ultrasound

TVS: Transvaginal ultrasound

2D-TVS: Two-dimensional transvaginal ultrasound

3D-TVS: Three-dimensional transvaginal ultrasound

ROI: Region of interest

NSAIDs: Non steroidal anti-inflammatory drugs

List of tables

Table		Page
Table(1)	Comparison of age in the menorrhagia and control groups	71
Table(2)	Comparison of age in the metrorrhagia and control groups	72
Table (3)	Comparison of age in the menorrhagia and metrorrhagia group	73
Table(4)	Comparison of parity in the menorrhagia and control groups	75
Table(5)	Comparison of parity in the metrorrhagia and control groups	76
Table(6)	Comparison of parity in the menorrhagia and metrorrhagia group	77
Table(7)	Comparison of duration of use in menorrhagia and control groups	79
Table(8)	Comparison of duration of use in metrorrhagia and control groups	80
Table(9)	Comparison of duration of use in menorrhagia and metrorrhagia groups	81
Table(10)	Comparison of IUCD-F distance in menorrhagia and control groups	83

Table(11)	Comparison of IUCD-F distance in metrorrhagia and control groups	85
Table(12)	Comparison of IUCD-F distance in menorrhagia and metrorrhagia groups	87
Table(13)	Comparison of IUCD-E distance in menorrhagia and control groups	90
Table (14)	Comparison of IUCD-E distance in metrorrhagia and control groups	92
Table(15)	Comparison of IUCD-E distance in menorrhagia and metrorrhagia groups	94
Table (16)	No of displaced IUCDs in menorrhagia and control groups	99
Table(17)	No of displaced IUCDs in metrorrhagia and control groups	100
Table(18)	No of displaced IUCDs in menorrhagia and metrorrhagia groups	101
Table (19)	Symptomatic relief within the study group after one month follow up	103

List of graphs

Graph		Page
Graph (1)	Mean age (years) among different study groups.	74
Graph (2)	Mean parity among different study groups.	78
Graph (3)	Mean duration of use among different study groups.	82
Graph (4)	Mean IUCD-F distance (mm) among menorrhagia and control groups	84
Graph (5)	Mean IUCD-F distance (mm) among metrorrhagia and control groups	86
Graph (6)	Mean IUCD-F distance (mm) among menorrhagia & metrorrhagia groups	88
Graph (7)	Mean IUCD-F distance (mm) among different study groups	89
Graph (8)	Mean IUCD-E distance (mm) among menorrhagia and control groups	91
Graph (9)	Mean IUCD-E distance (mm) among metrorrhagia and control groups	93
Graph (10)	Mean IUCD-E distance (mm) among menorrhagia & metrorrhagia groups	95
Graph (11)	Mean IUCD-E distance (mm) among different study groups	96

Graph(12)	Number of patients with displaced IUCDs in comparison to the total number of patients among different study groups	102
Graph(13)	Number of patients within the study group who experienced symptomatic relief after removal of the IUCD	104

List of figures

Figure		Page
Figure (1)	Different types of IUCDs	10
Figure (2)	Copper IUCD	11
Figure (3)	Mirena IUCD	11
Figure (4)	CuSAFE-300	12
Figure (5)	Gynefix	12
Figure (6)	Chinese ring	13
Figure (7)	New Chinese ring	13
Figure (8)	Perforating IUCD by X-ray	23
Figure (9)	An IUCD perforating posterior wall of the uterus	24
Figure (10)	Pregnancy with an IUCD insitu as seen by transvaginal ultrasound	28
Figure (11)	Sagital view of an IUCD by 2D-TVS	46